Established in 2010, Nephrocare Health Services Ltd. is an integrated dialysis care provider operating a widespread network of clinics. The company manages all aspects of care, from diagnosis and haemodialysis to home services and wellness programs, backed by its own pharmacy. By September 30, 2025, its global footprint included 519 clinics, with 51 located in the Philippines, Uzbekistan, and Nepal—including the world’s largest dialysis facility in Uzbekistan.
Within India, it served 288 cities across 21 states and 4 union territories, with over 77% of clinics situated in tier II and III cities to meet demand in less-served regions. In Fiscal 2025, it treated 29,281 patients and performed 2.88 million dialysis treatments—representing about 10% of India’s dialysis patient volume. To extend its reach, Nephrocare has entered collaborations with major hospital chains such as Max, Fortis, Care, and Wockhardt to operate in-house dialysis centres.
Nephrocare Health Services Limited is set to launch its book-built initial public offering (IPO), opening for subscription on December 10, 2025, and closing on December 12, 2025. The IPO aims to raise approximately ₹871.05 crores, structured as a fresh issue of ₹353.40 crores combined with an offer for sale of up to 1,12,53,102 equity shares, each with a face value of ₹2. The shares are being offered in a price band of ₹438 to ₹460.
The allocation is reserved with 35% for retail investors, 50% for qualified institutional buyers (QIBs), and 15% for non-institutional investors (HNIs). The tentative allotment date is December 15, 2025, with listing on both the BSE and NSE expected on December 17, 2025. Financially, the company has demonstrated significant growth, with revenue rising to ₹769.92 crores in the fiscal year 2025 from ₹574.72 crores in 2024, and profit more than doubling from ₹35.13 crores to ₹67.10 crores over the same period.
Nephrocare Health IPO Details
| IPO Date | December 10, 2025 to December 12, 2025 |
| Listing Date | [.] |
| Face Value | ₹2 per share |
| Issue Price Band | ₹438 to ₹460 Per Share |
| Lot Size | 32 Shares |
| Total Issue Size | Approx ₹871.05 Crores |
| Fresh Issue | Approx ₹353.40 Crores |
| Offer for Sale | Approx 1,12,53,102 Equity Shares |
| Issue Type | Book building IPO |
| Listing At | BSE, NSE |
| Share Holding Pre Issue | 9,26,50,799 shares |
| Share Holding Post Issue | 10,03,33,516 shares |
Nephrocare Health IPO Dates
The initial public offering (IPO) is scheduled to commence on Wednesday, December 10, 2025, and will conclude on Friday, December 12, 2025.
| IPO Open Date | Wed, Dec 10, 2025 |
| IPO Close Date | Fri, Dec 12, 2025 |
| Tentative Allotment | Mon, Dec 15, 2025 |
| Refunds | Tue, Dec 16, 2025 |
| Credit of Shares to Demat | Tue, Dec 16, 2025 |
| Tentative Listing Date | Wed, Dec 17, 2025 |
| UPI Mandate Confirmation Deadline | 5 PM on Fri, Dec 12, 2025 |
Nephrocare Health IPO Market Lot
Nephrocare Health IPO, the minimum application requirement for retail investors is one market lot, consisting of 32 shares at a total application amount of ₹14,720. Investors can apply for a maximum of 13 such lots, equating to a total of 416 shares with a corresponding maximum investment amount of ₹1,91,360.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 1 | 32 | ₹14,720 |
| Retail Maximum | 13 | 416 | ₹1,91,360 |
| S-HNI Minimum | 14 | 448 | ₹2,06,080 |
| S-HNI Maximum | 67 | 2,144 | ₹9,86,240 |
| B-HNI Minimum | 68 | 2,176 | ₹10,00,960 |
